Metronomic chemotherapy and tumor immunomodulation.
Bernacki
Ralph J
RJ
Department of Pharmacology & Therapeutics, Grace Cancer Drug Center, Roswell Park Cancer Institute, Elm & Carlton Streets, Buffalo, New York 14263, USA.
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols; D002166:Camptothecin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D051379:Mice; D008819:Mice, Nude; D009838:Oligodeoxyribonucleotides / Q000627:therapeutic use*; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D053220:Receptors, TNF-Related Apoptosis-Inducing Ligand / Q000378:metabolism; D053221:TNF-Related Apoptosis-Inducing Ligand / Q000378:metabolism; D023041:Xenograft Model Antitumor Assays
D000276:Adjuvants, Immunologic; C408982:CPG-oligonucleotide; D009838:Oligodeoxyribonucleotides; D053220:Receptors, TNF-Related Apoptosis-Inducing Ligand; C433984:ST 1481; D053221:TNF-Related Apoptosis-Inducing Ligand; D002166:Camptothecin